HSBC initiated coverage of Repligen (RGEN) with a Buy rating and $150 price target While biotech funding and the regulatory environment are headwinds for the company, its volume leverage in a recovery is underappreciated, the analyst tells investors in a research note. The firm believes Repligen’s portfolio in bioprocessing can drive double-digit revenue growth.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN: